FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia

Season 10 Episode 40  ·  Jul 01, 2024, 06:00 PM

Headliner
Share
Subscribe

Dr Sekeres discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Share
Subscribe
Next
ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air